Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Healive Vaccination Intervals in Adults
NCT06058416Phase 4Active, not recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2023
- Primary completion
- Mar 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hepatitis A vaccine (inactivated) in hepatitis A (HAV) (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: The seroconversion rate of anti-HAV antibody 28 days after two dose of vaccination of hepatitis A vaccine with an interval of 6 month and Incidence of adverse reaction within 28 days after one dose of vaccination. Started Oct 2023; status: active, not recruiting.
02
Drugs
hepatitis A vaccine (inactivated)
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT06058416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058416.